Tchaikapharma High Quality Medicines AD Full Year 2024 Earnings: EPS: лв0.055 (vs лв0.038 in FY 2023)

Tchaikapharma High Quality Medicines AD (BUL:THQM) Full Year 2024 Results

Key Financial Results

• Revenue: лв53.1m (up 9.5% from FY 2023).
• Net income: лв5.04m (up 48% from FY 2023).
• Profit margin: 9.5% (up from 7.0% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: лв0.055 (up from лв0.038 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Bulgaria segment contributing a total revenue of лв50.7m (95% of total revenue). Notably, cost of sales worth лв35.4m amounted to 67% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to лв9.09m (71% of total expenses). Explore how THQM's revenue and expenses shape its earnings.

Tchaikapharma High Quality Medicines AD's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Tchaikapharma High Quality Medicines AD that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.